Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1-targeted dendritic cell vaccination to prevent relapse in adult acute myeloid leukemia in remission
2012-001494-91Phase 2Active
- Sponsor
- Antwerp University Hospital
- Start
- Aug 2012
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of WT1 mRNA-loaded autologous monocyte-derived dendritic cells in acute myeloid leukemia (AML) (2 arms), sponsored by Antwerp University Hospital. Primary endpoint: Overall survival. Started Aug 2012; status: active.
02
Drugs
WT1 mRNA-loaded autologous monocyte-derived dendritic cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2012-001494-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001494-91.